Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,402 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dysplasia Mild Clear all
Recruiting Not applicable Interventional

CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms

NCT05663034
View directory record Official record
Conditions
Traumatic Brain Injury, Insomnia, Depression, Post-traumatic Stress, Sleep, Memory Impairment, Cognitive Behavioral Therapy, Concussion, Brain, Head Injury, Brain Injury Traumatic Mild
Interventions
Mindfulness-based treatment for insomnia (MBTI), Cognitive behavioral therapy for insomnia (CBT-I)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Eglin Air Force Base, Florida • Bethesda, Maryland • Fort Bragg, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 3:53 PM EDT
Not listed Phase 1Phase 2 Interventional

Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease

NCT01099332
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose
Other
Lead sponsor
Adeona Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Clearwater, Florida • Holiday, Florida • Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2011 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

NCT05599932
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Siremadlin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00406458
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Normal Saline
Drug · Other
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
14
States / cities
La Jolla, California • Lakewood, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Not applicable Interventional

Network-guided TMS in Early Alzheimer's Disease

NCT04549155
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Duke University
Other
Eligibility
55 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Alternative Therapy for Improving Cognition, Balance, and Physical Activity

NCT04160299
View directory record Official record
Conditions
Mild Cognitive Impairment, Older Adults, Neurological Injury
Interventions
Dance-based exergaming
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
65 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Not applicable Interventional

Microbiota-targeted Diet for Pediatric UC

NCT02922881
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ulcerative Colitis Diet (UCD)
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 19 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

NCT03471871
View directory record Official record
Conditions
Obstructive Sleep Apnea, Healthy Subjects
Interventions
Placebo, Lemborexant 10 mg, Lemborexant 25 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
11
States / cities
Glendale, Arizona • Phoenix, Arizona • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

NCT00698464
View directory record Official record
Conditions
Hepatic Cirrhosis, Alcoholism
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

NCT00685698
View directory record Official record
Conditions
Diabetic Foot Infections
Interventions
TG-873870 (Nemonoxacin)
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Montebello, California • Pasadena, California • Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 20, 2026, 3:53 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging of Brain Amyloid Plaques in the Aging Population

NCT00950430
View directory record Official record
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
Interventions
Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 100 Years
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients

NCT00643227
View directory record Official record
Conditions
Pneumonia
Interventions
clarithromycin extended release (ER), azithromycin SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Oct 20, 2026, 3:53 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

NCT06125951
View directory record Official record
Conditions
Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions
Xanamem, Placebo
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 3:53 PM EDT
Recruiting Not applicable Interventional

Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's

NCT05748613
View directory record Official record
Conditions
Anxiety, Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Computerized Anxiety Sensitivity Treatment, Health Education Control
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
60 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Tallahassee, Florida • Athens, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 20, 2026, 3:53 PM EDT
Completed No phase listed Observational

Service Member Fatigue and Lack of Motivation Following Concussion

NCT01496586
View directory record Official record
Conditions
Fatigue, Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Results available

Adult Oral Ibuprofen Study for ED Pain Patients

NCT03441269
View directory record Official record
Conditions
Pain, Acute
Interventions
Oral Ibuprofen
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 120 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 20, 2026, 3:53 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

NCT03759041
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vancomycin Pre-Treatment, Placebo for Vancomycin Pre-Treatment, SER-287, Placebo for SER-287
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
81
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Phase 2 Interventional

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

NCT00685529
View directory record Official record
Conditions
COPD
Interventions
Racemic formoterol, Arformoterol tartrate inhalation solution
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
Long Beach, California • Fort Lauderdale, Florida • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 20, 2026, 3:53 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

NCT03307512
View directory record Official record
Conditions
Safety and Tolerability
Interventions
inhaled human insulin, Insulin Lispro (Humalog U-100)
Drug
Lead sponsor
Dance Biopharm Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 20, 2026, 3:53 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Measuring Head Impacts in Sports

NCT00060827
View directory record Official record
Conditions
Brain Injuries, Brain Concussion
Interventions
Head Impact Recording Technology (HIRT)
Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 24 Years · Male only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Results available

Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis

NCT01093469
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Atopiclair Nonsteroidal Cream, Aquaphor Healing Ointment, EpiCeram
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 20, 2026, 3:53 PM EDT
Terminated Not applicable Interventional

Early Oral Nutrition in Mild Acute Pediatric Pancreatitis

NCT01423786
View directory record Official record
Conditions
Acute Pediatric Pancreatitis
Interventions
Early Oral Nutrition
Dietary Supplement
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Wear-Time Trial for Self-Fitting Hearing Aid

NCT04823494
View directory record Official record
Conditions
Hearing Loss, Sensorineural
Interventions
Hearing aids
Device
Lead sponsor
GN Hearing A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Palos Hills, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 20, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

NCT01028053
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Flutemetamol (18F) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
60 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 20, 2026, 3:53 PM EDT